Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
NCT00094991Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2004
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of muraglitazar in type 2 diabetes mellitus (T2DM), sponsored by Bristol Myers Squibb. Primary endpoint: Change from baseline in insulin mediated glucose disposal at 16 weeks. Started May 2004; status: completed.
02
Drugs
muraglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00094991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094991.